PTPN11 and colorectal carcinoma: We found that levels of phosphorylated SHP2 were consistently increased across several CRC cell lines by low-dose celastrol alone, and the combination of SHP099 (a selective SHP2 inhibitor) with low-dose celastrol obviously suppressed CRC cell growth in both in vitro and in vivo models.